Skip to main content
Terug
XNCR logo

Xencor, Inc.

Datakwaliteit: 100%
XNCR
NASDAQ Healthcare Biotechnology
€ 11,89
▼ € 0,16 (-1,33%)
Marktkapitalisatie: 872,00M
Dagbereik
€ 11,04 € 12,01
52-Weeksbereik
€ 6,92 € 18,69
Volume
1.230.502
50D / 200D Gem.
€ 12,31 / € 11,72
Vorige Slotkoers
€ 12,05

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E -9,5 0,4
P/B 1,4 2,9
ROE % -14,0 3,9
Net Margin % -73,2 3,8
Rev Growth 5Y % -17,8 10,0
D/E 0,3 0,2

Koersdoel Analisten

Hold
€ 28,75 +141.8%
Low: € 18,00 High: € 42,00
Forward WPA
-€ 2,88
Omzet Sch.
120 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 0,04
€ 0,00 – € 0,11
530 M 3
FY2029 -€ 1,46
-€ 3,72 – € 0,10
270 M 3
FY2028 -€ 2,70
-€ 4,08 – -€ 0,75
170 M 9

Belangrijkste Punten

Revenue declined -17,80% annually over 5 years
Debt/Equity of 0,30 — conservative balance sheet
Negative free cash flow of -138,27M
PEG of 0,19 suggests growth is underpriced
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 31,45%
Capital efficient — spends only 2,51% of revenue on capex

Groei

Revenue Growth (5Y)
-17,80%
Revenue (1Y)13,65%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-14,00%
ROIC-16,17%
Net Margin-73,20%
Op. Margin-141,35%

Veiligheid

Debt / Equity
0,30
Current Ratio6,25
Interest Coverage-5,56

Waardering

P/E Ratio
-9,49
P/B Ratio1,37
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 13,65% Revenue Growth (3Y) -15,20%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -17,80% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 125,58M Net Income (TTM) -91,92M
ROE -14,00% ROA -10,50%
Gross Margin 91,63% Operating Margin -141,35%
Net Margin -73,20% Free Cash Flow (TTM) -138,27M
ROIC -16,17% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,30 Current Ratio 6,25
Interest Coverage -5,56 Dividend Yield 0,00%
Valuation
P/E Ratio -9,49 P/B Ratio 1,37
P/S Ratio 6,94 PEG Ratio 0,19
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 872,00M Enterprise Value 1,01B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 125,58M 110,49M 174,62M 164,58M 275,11M
Net Income -91,92M -232,62M -133,13M -55,18M 82,63M
EPS (Diluted) -1,24 -3,58 -2,08 -0,93 1,37
Gross Profit 115,06M 110,49M 174,62M 164,58M 275,11M
Operating Income -177,50M -178,41M -132,36M -82,47M 43,77M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 875,50M 951,95M 952,69M 846,27M 838,21M
Total Liabilities 239,91M 277,92M 283,56M 118,77M 104,71M
Shareholders' Equity 635,59M 677,61M 668,80M 727,50M 733,50M
Total Debt 187,75M 231,95M 83,43M 59,63M 33,97M
Cash & Equivalents 54,07M 40,88M 53,79M 53,94M 143,48M
Current Assets 599,82M 577,60M 623,16M 675,34M 424,37M
Current Liabilities 95,91M 87,43M 84,71M 63,84M 70,74M